These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 25453735)

  • 41. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Iwata N
    CNS Drugs; 2013 Sep; 27(9):731-41. PubMed ID: 23812802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials.
    Zheng W; Cai DB; Yang XH; Li L; Zhang QE; Ng CH; Ungvari GS; Li XB; Ning YP; Xiang YT
    J Psychiatr Res; 2018 Aug; 103():244-251. PubMed ID: 29906709
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia.
    Loebel AD; Siu CO; Cucchiaro JB; Pikalov AA; Harvey PD
    CNS Spectr; 2014 Apr; 19(2):197-205. PubMed ID: 24330860
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.
    Loebel A; Cucchiaro J; Silva R; Mao Y; Xu J; Pikalov A; Marder SR
    Eur Psychiatry; 2015 Jan; 30(1):26-31. PubMed ID: 25280429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.
    Tarazi FI; Riva MA
    Expert Opin Drug Discov; 2013 Oct; 8(10):1297-307. PubMed ID: 23837554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder.
    Alamo C; López-Muñoz F; García-García P
    Expert Rev Neurother; 2014 Jun; 14(6):593-605. PubMed ID: 24779382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.
    Miura I; Horikoshi S; Ichinose M; Suzuki Y; Watanabe K
    Drug Des Devel Ther; 2023; 17():3023-3031. PubMed ID: 37789971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study.
    Harvey PD; Siu CO; Ogasa M; Loebel A
    Schizophr Res; 2015 Aug; 166(1-3):334-8. PubMed ID: 26117157
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia.
    Miller BJ; Pikalov A; Siu CO; Tocco M; Tsai J; Harvey PD; Newcomer JW; Loebel A
    Compr Psychiatry; 2020 Oct; 102():152195. PubMed ID: 32896775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lurasidone (Latuda) for schizophrenia.
    Med Lett Drugs Ther; 2011 Feb; 53(1358):13-4. PubMed ID: 21372761
    [No Abstract]   [Full Text] [Related]  

  • 53. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study.
    Loebel A; Cucchiaro J; Xu J; Sarma K; Pikalov A; Kane JM
    Schizophr Res; 2013 Jun; 147(1):95-102. PubMed ID: 23583011
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation.
    Loebel A; Citrome L; Correll CU; Xu J; Cucchiaro J; Kane JM
    BMC Psychiatry; 2015 Oct; 15():271. PubMed ID: 26521019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
    Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
    Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T; Samalin L; Llorca PM
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.